# A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19

> **NCT05981846** · PHASE2 · COMPLETED · sponsor: **Hipra Scientific, S.L.U** · enrollment: 279 (actual)

## Conditions studied

- SARS CoV 2 Infection
- Influenza, Human

## Interventions

- **BIOLOGICAL:** BIMERVAX
- **BIOLOGICAL:** SIIV

## Key facts

- **NCT ID:** NCT05981846
- **Lead sponsor:** Hipra Scientific, S.L.U
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-04
- **Primary completion:** 2023-10-09
- **Final completion:** 2023-11-06
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05981846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05981846, "A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05981846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*